This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

CompLaw: Pharma
December 2024
Venue TBCBrussels, Belgium
December 2024|Venue TBC, Brussels, Belgium

CompLaw: Pharma

The only European conference focusing specifically on competition law in the pharma sector

On-demand Content Now Available

If you're interested in purchasing recordings of the conference sessions please email

We have started putting the 2024 programme together. If you would like to be kept up to date, you can register your interest by downloading last year's agenda here.

Your essential 1-day update. Highlights for 2023 included:

Hear from the Regulators

Hear directly from Paul Csiszár, Director “Basic Industries, Manufacturing and Agriculture”, DG Competition, European Commission on the current priorities in the sector and ask your burning questions during the Q&A.

Then join the 'Enforcement: Review of National Level Developments' session to hear from the NCAs on their recent investigations. 

Horizontal Block Exemption Regulations

Review the Horizontal Block Exemption Regulations and revised Horizontal Guidelines and their practical implications for the pharma sector, including co-promotion and co-marketing, joint R&D, joint purchasing, information exchange and sustainability. Then discuss the CMA’s consultation on the rules applicable to collaborations and information exchange between competitors.

Article 102 Developments

Examine the EC’s consultation on the formal guidelines on the application of Article 102 TFEU to exclusionary abuses of dominance and, gain an update on the recent cases including Leadiant, CMA's decision against Pfizer and Flynn, and the Spanish Supreme Court’s judgement on the Pfizer dual-pricing case. Consider what is legitimate in discounts and rebates as understand the competition law concerns in cost-containment strategies. 

Merger Control, FDI & FSR

Analyse how the enforcers are using their new tools to facilitate a more interventionist approach, including the use of Article 22 and its implications for merger control strategy, the Towercast judgementand ex-post reviews. 

Join a new session focusing specifically on foreign direct investment and Foreign Subsidies Regulation, and how they apply to the pharma sector. 

Parallel Trade & Other Challenges in Distribution

Discuss parallel trade developments across Europe as well as refusal to supply, direct to pharmacy models and competition law considerations relating to tensions in the supply chain and analyse what these mean for distribution strategies.

Developments in Patents

Gain an update on recent investigations including Teva and Novartis, get a review of national-level developments including the Spanish authority's fines on Merck and understand how the enforcers are approaching biologics and biosimilars. Share practical strategies to address end of patent life, divisional game and patent pooling. 

Best practice session: strategies to address common challenges in the pharma sector

A new session designed to offer practical insights into common challenges within the sector. This session will be made of a series of mini presentations from experts in the field, focusing on a particular challenges, including:

Labour markets & competition law

Biologics and biosimilars

Divisional game

B Vos

Eli Lilly & Co

Of great practical relevance for in-house counsel in the pharmaceutical sector.

Sponsorship opportunities

We have a number of exclusive and innovative sponsorship and speaking options, to help you demonstrate thought leadership.

For more information please contact Enes Duzen on or call +44 (0) 20 8052 0469.